ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,021.63
0.57%
US Tech 100
20,355.20
0.45%
다우존스 지수
44,860.31
0.28%
Bitcoin
92,688.26
0.77%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Acrivon Therapeutics Inc (ACRV)

  7. Acrivon Therapeutics Inc (ACRV) 뉴스

ACRV

Acrivon Therapeutics (ACRV)

Acrivon Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:ACRV
일자시간출처헤드라인심볼기업
2024/11/2606:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/11/1906:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/11/1906:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/11/1906:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/11/1906:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/11/1906:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/11/1906:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/11/1321:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRVAcrivon Therapeutics Inc
2024/11/1321:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
2024/11/1321:00GlobeNewswire Inc.Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
2024/10/2205:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/10/1721:00GlobeNewswire Inc.Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR SymposiumNASDAQ:ACRVAcrivon Therapeutics Inc
2024/10/1705:00GlobeNewswire Inc.Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ACRVAcrivon Therapeutics Inc
2024/10/1121:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
2024/10/1121:00GlobeNewswire Inc.Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent ActivityNASDAQ:ACRVAcrivon Therapeutics Inc
2024/10/0407:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/09/1619:43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
2024/09/1416:10GlobeNewswire Inc.Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data AnalysisNASDAQ:ACRVAcrivon Therapeutics Inc
2024/09/1021:00GlobeNewswire Inc.Acrivon Therapeutics to Present at the Cantor Global Healthcare ConferenceNASDAQ:ACRVAcrivon Therapeutics Inc
2024/09/0920:00GlobeNewswire Inc.Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316NASDAQ:ACRVAcrivon Therapeutics Inc
2024/08/2405:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/08/1705:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/08/1705:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/08/1705:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/08/1705:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/08/1705:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/08/1705:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/08/1705:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRVAcrivon Therapeutics Inc
2024/08/1321:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRVAcrivon Therapeutics Inc
2024/08/1321:00GlobeNewswire Inc.Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsNASDAQ:ACRVAcrivon Therapeutics Inc
 검색 관련기사 보기:NASDAQ:ACRV

최근 히스토리

NYSE
MRK
Merck
NYSE
NKE
Nike
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
KO
Coca Cola
COIN
ETHUSD
Ethereum
COIN
ADAUSD
Cardano
USOTC
ADDYY
Adidas (QX)
AMEX
SPY
SPDR S&P 500
CCOM
US100
US Tech 100
NASDAQ
NVDA
NVIDIA
COIN
BTCUSD
Bitcoin
AMEX
XLE
Energy Select Sector SPDR
USOTC
RHHBY
Roche (QX)
NASDAQ
AMZN
Amazon.com
COIN
AVAXUSD
Avalanche
NYSE
VZ
Verizon Communications
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유